Orforglipron

1. Orforglipron has no effect on major adverse cardiovascular events in humans (HR 0.84 (95% CI 0.59–1.20)).

   Human trialtype 2 diabetes at increased cardiovascular riskcapsuleup to 36 mg capsulemedian follow-up of 2 yearsn = 2,749

   Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial · Lancet (London, England) · 30 Sep 2026

1. Orforglipron decreases non-HDL cholesterol in humans (−30.5 mg/dL (P=0.04)).

   Humansduring Foundayo usen = 11

   Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users · Preprints.org · 28 Sep 2026 · Preprint

non-HDL cholesterol →

1. Orforglipron increases body weight in humans (5.3% vs 2.4% (RR 2.20; P=0.016)).

   Humansrelative to oral Wegovy

   Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users · Preprints.org · 28 Sep 2026 · Preprint

1. Orforglipron lowers the risk of hypoglycemia in humans.

   Human trialtype 2 diabetes at increased cardiovascular riskcapsuleup to 36 mg capsulen = 2,749

   Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial · Lancet (London, England) · 30 Sep 2026